Repligen Co. (NASDAQ:RGEN) Receives $184.73 Average PT from Analysts

Shares of Repligen Co. (NASDAQ:RGEN - Get Free Report) have been assigned an average rating of "Moderate Buy" from the fourteen brokerages that are presently covering the company, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $184.73.

Several research firms recently weighed in on RGEN. StockNews.com raised Repligen from a "sell" rating to a "hold" rating in a report on Friday, January 3rd. Canaccord Genuity Group began coverage on shares of Repligen in a research report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 target price for the company. HC Wainwright decreased their price target on shares of Repligen from $240.00 to $180.00 and set a "buy" rating on the stock in a research note on Thursday, January 23rd. Canaccord Genuity Group initiated coverage on shares of Repligen in a report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 price objective for the company. Finally, Wolfe Research began coverage on shares of Repligen in a research report on Thursday, November 14th. They set a "peer perform" rating on the stock.

Repligen Stock Performance

Shares of NASDAQ:RGEN traded down $5.81 on Thursday, hitting $156.05. The company had a trading volume of 409,305 shares, compared to its average volume of 563,368. The stock has a market cap of $8.74 billion, a price-to-earnings ratio of -421.75, a P/E/G ratio of 4.54 and a beta of 0.99. The stock has a 50 day moving average price of $155.37 and a 200 day moving average price of $148.93. Repligen has a 1-year low of $113.50 and a 1-year high of $211.13. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, beating analysts' consensus estimates of $0.34 by $0.09. The business had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. Repligen's quarterly revenue was up 9.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.23 EPS. Analysts expect that Repligen will post 1.54 EPS for the current year.

Institutional Investors Weigh In On Repligen

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. UMB Bank n.a. raised its holdings in shares of Repligen by 138.3% during the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company's stock worth $33,000 after buying an additional 130 shares in the last quarter. Blue Trust Inc. raised its stake in Repligen by 113.4% during the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company's stock worth $36,000 after acquiring an additional 127 shares in the last quarter. Resources Management Corp CT ADV bought a new position in shares of Repligen in the third quarter worth about $37,000. Quarry LP lifted its holdings in shares of Repligen by 796.7% in the third quarter. Quarry LP now owns 269 shares of the biotechnology company's stock worth $40,000 after acquiring an additional 239 shares during the last quarter. Finally, nVerses Capital LLC acquired a new stake in shares of Repligen in the 3rd quarter valued at approximately $45,000. 97.64% of the stock is currently owned by institutional investors.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.